N/A
Manufactured by Haleon US Holdings LLC
12,550 FDA adverse event reports analyzed
Last updated: 2026-04-15
ACETAMINOPHEN, CAFFEINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Haleon US Holdings LLC. The most commonly reported adverse reactions for ACETAMINOPHEN, CAFFEINE include DRUG INEFFECTIVE, HEADACHE, NAUSEA, FATIGUE, PRODUCT USE IN UNAPPROVED INDICATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ACETAMINOPHEN, CAFFEINE.
Out of 7,381 classified reports for ACETAMINOPHEN, CAFFEINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 12,550 FDA FAERS reports that mention ACETAMINOPHEN, CAFFEINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, HEADACHE, NAUSEA, FATIGUE, PRODUCT USE IN UNAPPROVED INDICATION, MIGRAINE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Haleon US Holdings LLC in connection with ACETAMINOPHEN, CAFFEINE. Always verify the specific product and NDC with your pharmacist.